tiprankstipranks
Advertisement
Advertisement
Spyre Therapeutics price target raised to $100 from $80 at Wedbush
PremiumThe FlySpyre Therapeutics price target raised to $100 from $80 at Wedbush
14d ago
Spyre Therapeutics: Buy Rating Reaffirmed as Positive SPY002 Ulcerative Colitis Data Supports $103 Price Target
Premium
Ratings
Spyre Therapeutics: Buy Rating Reaffirmed as Positive SPY002 Ulcerative Colitis Data Supports $103 Price Target
14d ago
Julian Harrison Reiterates Buy on Spyre Therapeutics, Lifts Price Target to $112 on Encouraging SPY002 Ulcerative Colitis Data and TL1A Platform Validation
Premium
Ratings
Julian Harrison Reiterates Buy on Spyre Therapeutics, Lifts Price Target to $112 on Encouraging SPY002 Ulcerative Colitis Data and TL1A Platform Validation
14d ago
Spyre Therapeutics completes enrollment in SKYWAY basket trial of SPY072
PremiumThe FlySpyre Therapeutics completes enrollment in SKYWAY basket trial of SPY072
27d ago
Spyre Expands SPY003 Rights Beyond Inflammatory Bowel Disease
Premium
Company Announcements
Spyre Expands SPY003 Rights Beyond Inflammatory Bowel Disease
28d ago
Spyre Therapeutics Shareholders Back Board, Governance Proposals
Premium
Company Announcements
Spyre Therapeutics Shareholders Back Board, Governance Proposals
1M ago
Julian Harrison Reiterates Buy on Spyre Therapeutics, Maintains $98 Price Target on Strong IBD Pipeline and Cash Runway
PremiumRatingsJulian Harrison Reiterates Buy on Spyre Therapeutics, Maintains $98 Price Target on Strong IBD Pipeline and Cash Runway
2M ago
Spyre Therapeutics’ Exclusive Forum Clauses Shift Legal Leverage, Raise Venue and Litigation Cost Concerns for Stockholders
Premium
Company Announcements
Spyre Therapeutics’ Exclusive Forum Clauses Shift Legal Leverage, Raise Venue and Litigation Cost Concerns for Stockholders
2M ago
Spyre Therapeutics reports Q1 EPS (74c), consensus (65c)
Premium
The Fly
Spyre Therapeutics reports Q1 EPS (74c), consensus (65c)
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100